Multi-targeted RNAi therapeutics for scarless wound healing of skin
US RE46,873 In forceTerm ends Jul 13, 2029 · From the USPTO record
20-year base term ends Nov 6, 2028
Nov 6, 2008
Jul 13, 2029
May 29, 2018
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 6, 2008, when the earliest non-provisional application in its chain was filed (this one was filed May 26, 2016) | Nov 6, 2028 | High confidence |
| Continuity chain | A reissue: its term follows the original patent's, with the original's term adjustment | follows the original patent | Medium confidence |
| Patent term adjustment | +249 days, the original patent's USPTO patent term adjustment record, which governs a reissue (35 U.S.C. 251). This reissue's own record carries none | Jul 13, 2029 | Medium confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jul 13, 2029 | From the USPTO record |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.